GlassScriptPhysician profile
Larry Skelton
NPI 1245207448
$3,393.06
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $820 · 2021: $667 · 2022: $656 · 2023: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $489 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $489.11 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $575.54 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $514.33 | 2021-2023 | Vraylar, Qulipta |
| Lilly USA, LLC | $333.04 | 2019-2023 | Mounjaro |
| Allergan, INC. | $235.58 | 2019-2020 | |
| Pfizer INC. | $235.25 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $186.33 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $185.41 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $139.24 | 2019-2021 | |
| Daiichi Sankyo INC. | $120.82 | 2022 | |
| Merck Sharp & Dohme LLC | $103.47 | 2020-2021 | |
| Astellas Pharma US INC | $94.00 | 2023 | |
| Amgen INC. | $93.56 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.58 | 2019-2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $72.45 | 2020-2022 | |
| Glaxosmithkline, LLC. | $54.44 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $47.33 | 2021-2023 | |
| Dexcom, INC. | $43.97 | 2021-2023 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $36.52 | 2023 | Edarbi |
| Supernus Pharmaceuticals, INC. | $30.39 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $24.75 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.76 | 2022 | |
| Genentech USA, INC. | $19.25 | 2019 | |
| Xeris Pharmaceuticals, INC. | $18.73 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.16 | 2022 | |
| Exact Sciences Corporation | $16.59 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.00 | 2022 | |
| Athena Bioscience, LLC | $15.62 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.45 | 2022 | |
| Jazz Pharmaceuticals INC. | $12.52 | 2021 | |
| Adlon Therapeutics L.P. | $11.87 | 2020 | |
| Eisai INC. | $11.65 | 2021 | |
| Corium, LLC | $11.46 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Skelton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.